Abstract
Objective To study the curative effects of octreotide combined with letrozole on recurrent metastasis breast cancer patients. Methods The 61 recurrent metastasis breast cancer patients whose expression of somatostatin receptor (SSTR), estrogen receptor (ER) and/or progesterone receptor(PR) were positive were divided into 3 groups: 9 cases in group A (non-treatment group), 21 cases in group B (letrozole therapy group), and 21 cases in group C (octreotide combined with letrozole therapy group). The 6, 12, 18, and 24 months survival rate and life quality were compared between the 3 groups. Results The 6, 12, 18, and 24 months survival rate was 11.1% (1/9) , 0% (0/9) , 0% (0/9) , and 0% (0/9) respectively in group A, while it was 76.2% (16/21) , 28.6% (6/21) , 9.5%(2/21) , and 4.8% (1/21) in group B, and 93.5% (29/31) , 64.5% (20/31) , 41.9% (13/31) , and 12.9% (4/31) in group C. The difference of 6, 12, and 18 months survival rate between the 3 groups were statistically diffenent (P<0.05) . The life quality of group C was better than that of group A and group B. Conclusions Octreotide may be a new targeted drug to treat recurrent metastasis breast cancer with positive SSTR. Octreotide combined letrozole can improve the survival rate of breast cancer, and it is easy to be accepted by patients, with good compliance. Key words: Octreotide; Letrozole; Recurrent metastasis breast cancer
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
